Metabolic syndrome in patients with schizophrenia treated with antipsychotics : Attitudes from psychiatrists

被引：0
|
作者：
Pelayo-Teran, J. M.
Zapico-Merayo, Y. [1 ]
Alonso-Fernandez, A. R. [1 ]
Martinez-Diez, J. [2 ]
机构：
[1] Hosp El Bierzo, Ponferrada, Spain
[2] AGC Salud Mental Arriondas, Arriondas, Spain
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-01-051
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [41] Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
    De Hert, M.
    van Winkel, R.
    Van Eyck, D.
    Hanssens, L.
    Wampers, M.
    Scheen, A.
    Peuskens, J.
    DRUG SAFETY, 2006, 29 (10) : 980 - 980
  • [42] Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
    Jaberi, Nayyer
    Faramarzi, Elnar
    Farahbakhsh, Mostafa
    Ostadarahimi, Alireza
    Jafarabadi, Mohammad Asghari
    Fakhari, Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2020, 11 (03) : 310 - 314
  • [43] Ziprasidone switching effects on metabolic syndrome in patients treated with others atypical antipsychotics
    Grigorescu, R.
    Voicu, V.
    Vasile, D.
    Grigorescu, G.
    Staicu, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S495 - S495
  • [44] Inflammatory cytokines and features of the metabolic syndrome among patients treated with atypical antipsychotics
    Alméras, N
    Demers, MF
    Villeneuve, J
    Roy, MA
    Bouchard, RH
    Després, JP
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 350 - 351
  • [45] Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
    De Hert, MA
    van Winkel, R
    Van Eyck, D
    Hanssens, L
    Wampers, M
    Scheen, A
    Peuskens, J
    SCHIZOPHRENIA RESEARCH, 2006, 83 (01) : 87 - 93
  • [46] Interventions in antipsychotics-treated patients with cardiometabolic risk factors or metabolic syndrome
    Larsen, J.
    Holdrup, M.
    Christensen, B.
    Sigalin, C.
    Nilsson, P. M.
    Kolb, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S440 - S441
  • [47] Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
    Riordan, Henry J.
    Antonini, Paola
    Murphy, Michael F.
    AMERICAN HEALTH AND DRUG BENEFITS, 2011, 4 (05): : 292 - 301
  • [48] Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics
    Chen, Po-Yu
    Chen, Chun-Hsin
    Chang, Chin-Kuo
    Kao, Chung-Feng
    Lu, Mong-Liang
    Lin, Shih-Ku
    Huang, Ming-Chyi
    Hwang, Ling-Ling
    Mondelli, Valeria
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (01): : 28 - 36
  • [49] Risk Factors Associated With Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics The Role of Folate Pharmacogenetics
    Ellingrod, Vicki L.
    Taylor, Stephan F.
    Dalack, Gregory
    Grove, Tyler B.
    Bly, Michael J.
    Brook, Robert D.
    Zoellner, Sebastian K.
    Pop-Busui, Rodica
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (02) : 261 - 265
  • [50] Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists
    Hamann, J
    Pfeiffer, H
    Leucht, S
    Kissling, W
    PHARMACOPSYCHIATRY, 2003, 36 (06) : 309 - 312
12345